Department of Nephrology, Dialysis and Transplantation, S. Bortolo Hospital, Vicenza, Italy.
Intensive Care Med. 2015 Jun;41(6):985-93. doi: 10.1007/s00134-015-3807-0. Epub 2015 Apr 17.
More than 20 years have passed since the first clinical application of continuous renal replacement therapy (CRRT) in children. In that revolutionary era, before roller pumps and dialysis monitors for intensive care units were readily available, continuous arteriovenous hemofiltration was the most common treatment for critically ill children.
Those steps were the basis for current knowledge about modern CRRT. Research on circuit rheology and filter materials allowed for the improvement of materials, and the optimization of patency and session life spans. Hemofiltration was coupled with dialysis to increase dialytic dose and system efficiency. Several systems were required to optimize ultrafiltration and manage fluid overload. A quarter of a century later, another revolution is taking place. Acute renal failure has been recognized as a threatening syndrome, independently associated with mortality in critically ill children and characterized by a broad spectrum of clinical phenotypes. For this reason, it has been redefined as acute kidney injury (AKI). This condition is today accurately classified in both adults and children, and has been identified as a primary condition for prevention and aggressive treatment in all pediatric intensive care unit patients. Critically ill neonates and children with multiple organ dysfunction are certainly at higher risk of AKI. Finally, novel technology specifically dedicated to pediatric patients allows feasible and easy application of CRRT to infants and children: a new field of critical care nephrology, dedicated to pediatric patients, has been fully developed.
After 20 years, significant developments in critical care nephrology have taken place. Clinical and technical issues have both been addressed, and severe pediatric AKI can currently be managed with accurate and safe dialysis machines that will likely warrant outcome improvements over the following decade.
自连续肾脏替代疗法(CRRT)首次应用于儿科临床以来,已经过去了 20 多年。在那个革命性的时代,在重症监护室的滚压泵和透析监测仪尚未普及之前,连续动静脉血液滤过是治疗危重症儿童最常见的方法。
这些步骤是当前关于现代 CRRT 知识的基础。对回路流变学和过滤材料的研究使得材料得以改进,并优化了通畅性和治疗时间。血液滤过与透析相结合,以增加透析剂量和系统效率。需要几个系统来优化超滤并管理液体超负荷。四分之一个世纪后,另一场革命正在发生。急性肾衰竭已被认为是一种威胁性综合征,与危重症儿童的死亡率独立相关,并具有广泛的临床表型谱。因此,它被重新定义为急性肾损伤(AKI)。目前,成人和儿童都对这种疾病进行了准确的分类,并被确定为所有儿科重症监护病房患者预防和积极治疗的主要疾病。危重新生儿和多器官功能障碍的儿童肯定有更高的 AKI 风险。最后,专门为儿科患者设计的新技术使得 CRRT 可以在婴儿和儿童中可行且易于应用:一个专门针对儿科患者的危重病肾脏病学新领域已经得到充分发展。
20 年后,重症肾脏病学取得了重大进展。临床和技术问题都得到了解决,目前严重的儿科 AKI 可以通过准确和安全的透析机来治疗,这很可能会在未来十年内提高治疗效果。